TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,324,377 | -61.4% | 483,711 | -33.7% | 0.00% | -100.0% |
| Q2 2023 | $11,203,706 | -56.1% | 729,408 | -35.7% | 0.00% | -66.7% |
| Q1 2023 | $25,506,000 | +99071.8% | 1,134,151 | -7.3% | 0.00% | 0.0% |
| Q4 2022 | $25,719 | -99.9% | 1,222,958 | +15.7% | 0.00% | -25.0% |
| Q3 2022 | $26,044,000 | -2.1% | 1,057,003 | -3.7% | 0.00% | 0.0% |
| Q2 2022 | $26,602,000 | -4.8% | 1,097,937 | +1.2% | 0.00% | +33.3% |
| Q1 2022 | $27,949,000 | -20.6% | 1,084,568 | -4.4% | 0.00% | -25.0% |
| Q4 2021 | $35,216,000 | +48.8% | 1,134,509 | +16.2% | 0.00% | +33.3% |
| Q3 2021 | $23,672,000 | +53.6% | 976,140 | -7.6% | 0.00% | +50.0% |
| Q2 2021 | $15,415,000 | +2029.1% | 1,056,524 | +3544.9% | 0.00% | – |
| Q1 2021 | $724,000 | -26.0% | 28,986 | -19.3% | 0.00% | – |
| Q4 2020 | $979,000 | – | 35,909 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |